A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
出版年份 2018 全文链接
标题
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-11-23
DOI
10.1186/s40425-018-0442-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer – A systematic review and network meta-analysis of 3024 participants
- (2018) Pui San Tan et al. LUNG CANCER
- Economic sustainability of immune-checkpoint inhibitors: the looming threat
- (2018) Vivek Verma Nature Reviews Clinical Oncology
- Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab
- (2017) Francesco Passiglia et al. INTERNATIONAL JOURNAL OF CANCER
- Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma
- (2017) Christine G. Kohn et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Kathryn R Tringale et al. JNCI-Journal of the National Cancer Institute
- Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review
- (2017) Vivek Verma et al. JNCI-Journal of the National Cancer Institute
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost‐Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
- (2017) Mahdi Zargar et al. ONCOLOGIST
- Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆
- (2017) Matthew C. Ward et al. ORAL ONCOLOGY
- Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal
- (2017) Luis Silva Miguel et al. VALUE IN HEALTH
- Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Kathryn R Tringale et al. JNCI-Journal of the National Cancer Institute
- Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review
- (2017) Vivek Verma et al. JNCI-Journal of the National Cancer Institute
- Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting
- (2016) Beatriz Guglieri-López et al. ANTI-CANCER DRUGS
- A systematic review of the cost and cost-effectiveness studies of proton radiotherapy
- (2016) Vivek Verma et al. CANCER
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
- (2016) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing
- (2016) Klazien Matter-Walstra et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pharmaceutical Policy Reform — Balancing Affordability with Incentives for Innovation
- (2016) Rena M. Conti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
- (2016) Megan A. Bohensky et al. VALUE IN HEALTH
- Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
- (2016) Min Huang et al. JOURNAL OF MEDICAL ECONOMICS
- Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes
- (2016) Ron Goeree et al. JOURNAL OF MEDICAL ECONOMICS
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
- (2015) Roy L. Maute et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
- (2014) Patti Curl et al. PLoS One
- High Cancer Drug Prices in the United States: Reasons and Proposed Solutions
- (2014) Hagop Kantarjian et al. Journal of Oncology Practice
- The High Cost of Cancer Drugs and What We Can Do About It
- (2012) Mustaqeem Siddiqui et al. MAYO CLINIC PROCEEDINGS
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
- (2012) Victor Barzey et al. JOURNAL OF MEDICAL ECONOMICS
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
- (2010) David Moher et al. International Journal of Surgery
- What if the Federal Government Negotiated Pharmaceutical Prices for Seniors? An Estimate of National Savings
- (2008) Walid F. Gellad et al. JOURNAL OF GENERAL INTERNAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started